Prothena公共 PRTA 深 沪
交易中 11-21 10:12:49 美东时间
10.24
+0.190
+1.89%
华盛通- 最 高10.285
- 今 开10.02
- 成交量 4.80万股
- 最 低 9.90
- 昨 收 10.05
- 总市值 5.51亿
- 52周最高 17.66
- 市盈率 静 --
- 换手率 0.09%
- 52周最低 4.32
- 委 比 -49.88%
- 总股本 5383.00万
- 历史最高 79.749
- 量 比 1.28
- 振 幅 3.83%
- 历史最低 4.32
- 每 手 1
- 风险率 3.31%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Prothena Shareholders Approve Capital Reduction Proposal
Prothena ( ($PRTA) ) has provided an announcement. On November 19, 2025, Prothe...
11-20 06:06
Prothena Data From TDP-43 CYTOPE Program Demonstrates CYTOPE Technology's Potential To Deliver Large Molecules Into Cells
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, announced a scientific presentation at
11-20 05:09
Novo Nordisk's $100 Million Coramitug Shows Promise In Reducing Heart Failure Biomarker
Novo Nordisk's Coramitug cut NT-proBNP levels and was well tolerated in a Phase 2 ATTR-CM trial, paving the way for its Phase 3 CLEOPATTRA study.
11-12 22:24
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
11-10 17:17
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
11-10 10:22
RBC Capital Maintains Sector Perform on Prothena Corp, Raises Price Target to $11
RBC Capital analyst Brian Abrahams maintains Prothena Corp (NASDAQ:PRTA) with a Sector Perform and raises the price target from $10 to $11.
11-08 03:21
Earnings Scheduled For November 6, 2025
Companies Reporting Before The Bell • Clear Channel Outdoor (NYSE:CCO) is expec...
11-06 19:12
美股大行评级 | 上调！苹果、亚马逊、Amkor Tech、Cadence、Confluent、卡特、通用动力等获多家上调目标价
今日重点评级关注：HC Wainwright & Co.：维持PepGen"买入"评级，目标价从12美元升至18美元；Piper Sandler：维持Prothena Corp"超配"评级，目标价从15美元升至36美元
10-29 09:25
Piper Sandler Maintains Overweight on Prothena Corp, Raises Price Target to $36
Piper Sandler analyst Yasmeen Rahimi maintains Prothena Corp (NASDAQ:PRTA) with a Overweight and raises the price target from $15 to $36.
10-28 19:58
美股大行评级 | 最高300美元，AMD获多家大行上调目标价！
今日重点评级关注：Maxim Group：维持Gain Therapeutics"买入"评级，目标价从5美元升至7美元；HC Wainwright & Co.：维持Icecure Medical"买入"评级，目标价从2美元升至2.5美元
10-08 09:14
